BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250710T190000
DTEND;TZID=Africa/Nairobi:20250710T203000
DTSTAMP:20260528T094232
CREATED:20250414T201718Z
LAST-MODIFIED:20250806T125314Z
UID:24409-1752174000-1752179400@kesho-kenya.org
SUMMARY:Prostate Cancer
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””]Date: 10 July 2025 | Time: 7:00 – 8:30PM EAT \nModerator: Dr Ahmed Komen \nDr Muigai Mararo – Management Algorithm for Metastatic Prostate Cancer\nDr Mararo presented a concise framework detailing oligometastatic local therapies (stereotactic radiotherapy or nodal resection)\, first‑line androgen‑deprivation therapy (continuous orchiectomy or LHRH analogue) combined with AR pathway inhibitors or docetaxel (with or without triplet combinations)\, radiotherapy for low‑volume disease\, and the sequencing of novel agents (second‑generation antiandrogens\, PARP inhibitors\, radioligand therapy) in castration‑resistant settings\, alongside essential supportive measures (bone protection\, multidisciplinary review). \nDr. Syokau Ilovi – Role of Germline Genetic Testing in Prostate Cancer\nAbout 10% of prostate cancers harbor pathogenic germline variants (notably BRCA1/2 and other HRR genes)\, prompting universal testing in metastatic disease and selective panels in high‑risk localized cases; implementation includes multigene panels\, variant classification (pathogenic\, VUS)\, genetic counseling\, cascade testing for relatives\, and periodic reclassification to inform personalized therapy and family risk management. \nDr. Mercy Gatua – Advances in Management of Metastatic Prostate Cancer: The Role of PARP Inhibitors\nPARP inhibitors exploit homologous recombination repair deficiencies (up to 30% of mCRPC\, especially BRCA2 mutations) by inducing lethal double‑strand DNA breaks; key trials (TOPARP\, PROfound\, TRITON3\, PROpel) demonstrate significant rPFS and OS benefits as monotherapy or combined with AR pathway inhibitors in germline/somatic HRR‑mutated cohorts\, supporting FDA/EMA approvals and integration into first‑line and later‑line mCRPC treatment algorithms. \n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/prostate-cancer-6/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/WhatsApp-Image-2025-07-07-at-11.29.37-AM-e1751892629661.jpeg
END:VEVENT
END:VCALENDAR